Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Carlsmed is a pre-revenue medical technology company developing personalized spinal implant solutions using proprietary software and additive manufacturing. The company's aprevo platform combines AI-driven surgical planning software with patient-specific 3D-printed titanium implants for complex spinal deformity cases. With 73.8% gross margins on minimal revenue ($0.0B TTM) and 97.2% YoY growth from a near-zero base, Carlsmed is in early commercialization phase, burning cash at -$0.0B operating cash flow while maintaining strong liquidity (12.03x current ratio).
Carlsmed operates a razor-and-blade model where proprietary surgical planning software (aprevo) generates patient-specific implant designs that can only be manufactured by Carlsmed using additive manufacturing. Revenue is generated per surgical case through implant sales to hospitals and surgical centers, typically priced at premium to traditional off-the-shelf implants due to customization and improved surgical outcomes. The 73.8% gross margin suggests high-value product positioning, though scale is needed to cover R&D and commercialization costs. Competitive advantage stems from FDA clearances for patient-specific devices, surgeon network effects as early adopters train peers, and proprietary algorithms linking imaging data to implant geometry. Pricing power depends on demonstrating superior clinical outcomes (reduced revision rates, shorter surgery times) and securing reimbursement codes for personalized implants.
Quarterly case volume growth and surgeon adoption metrics (number of active surgeons, cases per surgeon)
FDA clearances for expanded indications or new spinal segments beyond current approvals
Hospital system partnership announcements and GPO (Group Purchasing Organization) contract wins
Clinical study results demonstrating superiority vs. traditional implants (revision rates, patient outcomes, OR time reduction)
Cash runway updates and financing announcements given negative operating cash flow
Reimbursement policy changes for patient-specific devices from CMS or private payers
Reimbursement uncertainty for patient-specific implants - CMS and private payers may not establish adequate reimbursement codes or coverage policies, limiting market adoption regardless of clinical efficacy
Regulatory pathway complexity - each design modification may require new FDA submissions, slowing product iteration vs. software-only competitors
Surgeon adoption barriers - requires significant training investment and workflow changes, creating high switching costs that slow market penetration
Manufacturing scalability - 3D printing production capacity constraints could limit growth if demand accelerates faster than manufacturing infrastructure
Large orthopedic incumbents (Medtronic, Stryker, Johnson & Johnson) developing competing patient-specific platforms with established surgeon relationships and distribution networks
Alternative surgical approaches (minimally invasive techniques, robotic surgery systems) that reduce need for complex custom implants
Commoditization risk if multiple competitors achieve similar customization capabilities, eroding pricing power and 73.8% gross margins
Cash burn sustainability - negative operating cash flow with minimal revenue requires continued equity financing, risking dilution if raised at unfavorable valuations
Going concern risk if unable to achieve commercialization milestones before cash depletion, though 12.03x current ratio suggests near-term runway
83.3% ROE driven by negative equity base (accumulated losses) rather than profitability, masking underlying financial stress
moderate - Elective spinal surgeries are partially discretionary and can be deferred during economic downturns, impacting case volumes. However, complex spinal deformities often require intervention regardless of economic conditions. Hospital capital budgets for new technologies contract during recessions, potentially slowing adoption. As pre-revenue company, Carlsmed's ability to raise capital is highly sensitive to risk appetite in growth equity markets, which correlates with broader economic conditions.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting 7.0x P/S valuation; (2) Increased cost of capital for future financing rounds dilutes existing shareholders; (3) Hospital systems face higher borrowing costs for capital equipment purchases, potentially slowing technology adoption cycles. Current 12.03x current ratio provides buffer, but future capital needs make rate environment critical for financing terms.
Minimal direct credit exposure as company sells to hospitals (typically strong credit) rather than extending patient financing. However, hospital financial stress during credit tightening can delay purchasing decisions and extend sales cycles. Company's own access to credit markets is critical given negative cash flow, though current balance sheet appears equity-financed (0.17 D/E ratio).
growth - Attracts speculative growth investors and healthcare-focused venture capital seeking exposure to personalized medicine and surgical innovation. 97.2% revenue growth (off minimal base) and -89.3% net margin profile typical of early-stage medical device companies pre-inflection. Not suitable for value or income investors given negative profitability and no dividend. Requires high risk tolerance and 3-5 year investment horizon to reach potential profitability.
high - Small-cap ($0.3B market cap) pre-revenue medical device companies exhibit extreme volatility driven by binary events (FDA decisions, clinical trial results, financing announcements). Limited trading liquidity amplifies price swings. Recent performance (-18.3% 1-year, -10.1% 6-month) reflects broader medtech growth stock compression. Expect continued high volatility until revenue scale and profitability visibility improve.
